329 related articles for article (PubMed ID: 15727486)
1. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Lentz F; Tran A; Rey E; Pons G; Tréluyer JM
Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486
[TBL] [Abstract][Full Text] [Related]
2. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
4. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
Volk J; Reinke F; van Kuilenburg AB; van Gennip AH; Schlichting C; Ganser A; Schöffski P
Ann Oncol; 2001 Apr; 12(4):569-71. PubMed ID: 11398894
[TBL] [Abstract][Full Text] [Related]
5. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
Braun MS; Richman SD; Quirke P; Daly C; Adlard JW; Elliott F; Barrett JH; Selby P; Meade AM; Stephens RJ; Parmar MK; Seymour MT
J Clin Oncol; 2008 Jun; 26(16):2690-8. PubMed ID: 18509181
[TBL] [Abstract][Full Text] [Related]
6. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
[TBL] [Abstract][Full Text] [Related]
7. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Rubbia-Brandt L; Giostra E; Brezault C; Roth AD; Andres A; Audard V; Sartoretti P; Dousset B; Majno PE; Soubrane O; Chaussade S; Mentha G; Terris B
Ann Oncol; 2007 Feb; 18(2):299-304. PubMed ID: 17060484
[TBL] [Abstract][Full Text] [Related]
8. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Schmoll HJ
Semin Oncol; 2002 Oct; 29(5 Suppl 15):34-9. PubMed ID: 12422306
[TBL] [Abstract][Full Text] [Related]
9. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F
Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Baba H; Watanabe M; Okabe H; Miyamoto Y; Sakamoto Y; Baba Y; Iwatsuki M; Chikamoto A; Beppu T
Br J Cancer; 2012 Dec; 107(12):1950-5. PubMed ID: 23169295
[TBL] [Abstract][Full Text] [Related]
11. FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Mohelnikova-Duchonova B; Melichar B; Soucek P
World J Gastroenterol; 2014 Aug; 20(30):10316-30. PubMed ID: 25132748
[TBL] [Abstract][Full Text] [Related]
12. The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Clin Colorectal Cancer; 2003 Feb; 2(4):205-9. PubMed ID: 12620138
[No Abstract] [Full Text] [Related]
13. Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Morelli MF; Santomaggio A; Ricevuto E; Cannita K; De Galitiis F; Tudini M; Bruera G; Mancini M; Pelliccione M; Calista F; Guglielmi F; Martella F; Lanfiuti Baldi P; Porzio G; Russo A; Gebbia N; Iacobelli S; Marchetti P; Ficorella C
Oncol Rep; 2010 Jun; 23(6):1635-40. PubMed ID: 20428819
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Punt CJ
Ann Oncol; 2005 Jun; 16(6):845-6. PubMed ID: 15890668
[No Abstract] [Full Text] [Related]
16. Current approaches to first-line treatment of advanced colorectal cancer.
Goldberg RM
Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S9-15. PubMed ID: 15212700
[TBL] [Abstract][Full Text] [Related]
17. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
18. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
Wicherts DA; de Haas RJ; Sebagh M; Ciacio O; Lévi F; Paule B; Giacchetti S; Guettier C; Azoulay D; Castaing D; Adam R
Ann Surg Oncol; 2011 Mar; 18(3):659-69. PubMed ID: 20976564
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Hejna M; Köstler WJ; Raderer M; Tomek S; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
Anticancer Drugs; 2000 Sep; 11(8):629-34. PubMed ID: 11081454
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
Volovat SR; Volovat C; Negru SM; Danciu M; Scripcariu V
J Chemother; 2016 Jun; 28(3):235-41. PubMed ID: 26018108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]